170 related articles for article (PubMed ID: 38526790)
1. CRISPR-Cas9-Mediated Bioluminescent Tagging of Endogenous Proteins by Fluorescent Protein-Assisted Cell Sorting.
Hawley RG; Hawley TS
Methods Mol Biol; 2024; 2779():273-286. PubMed ID: 38526790
[TBL] [Abstract][Full Text] [Related]
2. Modeling of the human alveolar rhabdomyosarcoma Pax3-Foxo1 chromosome translocation in mouse myoblasts using CRISPR-Cas9 nuclease.
Lagutina IV; Valentine V; Picchione F; Harwood F; Valentine MB; Villarejo-Balcells B; Carvajal JJ; Grosveld GC
PLoS Genet; 2015; 11(2):e1004951. PubMed ID: 25659124
[TBL] [Abstract][Full Text] [Related]
3. PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma.
Pandey PR; Chatterjee B; Olanich ME; Khan J; Miettinen MM; Hewitt SM; Barr FG
J Pathol; 2017 Apr; 241(5):626-637. PubMed ID: 28138962
[TBL] [Abstract][Full Text] [Related]
4. Aurora A Kinase Inhibition Destabilizes PAX3-FOXO1 and MYCN and Synergizes with Navitoclax to Induce Rhabdomyosarcoma Cell Death.
Ommer J; Selfe JL; Wachtel M; O'Brien EM; Laubscher D; Roemmele M; Kasper S; Delattre O; Surdez D; Petts G; Kelsey A; Shipley J; Schäfer BW
Cancer Res; 2020 Feb; 80(4):832-842. PubMed ID: 31888889
[TBL] [Abstract][Full Text] [Related]
5. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
6. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells.
Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J
Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416
[TBL] [Abstract][Full Text] [Related]
7. KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma.
Kim YY; Gryder BE; Sinniah R; Peach ML; Shern JF; Abdelmaksoud A; Pomella S; Woldemichael GM; Stanton BZ; Milewski D; Barchi JJ; Schneekloth JS; Chari R; Kowalczyk JT; Shenoy SR; Evans JR; Song YK; Wang C; Wen X; Chou HC; Gangalapudi V; Esposito D; Jones J; Procter L; O'Neill M; Jenkins LM; Tarasova NI; Wei JS; McMahon JB; O'Keefe BR; Hawley RG; Khan J
Nat Commun; 2024 Feb; 15(1):1703. PubMed ID: 38402212
[TBL] [Abstract][Full Text] [Related]
8. A Fusion Transcription Factor-Driven Cancer Progresses to a Fusion-Independent Relapse via Constitutive Activation of a Downstream Transcriptional Target.
Boudjadi S; Pandey PR; Chatterjee B; Nguyen TH; Sun W; Barr FG
Cancer Res; 2021 Jun; 81(11):2930-2942. PubMed ID: 33589519
[TBL] [Abstract][Full Text] [Related]
9. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
[TBL] [Abstract][Full Text] [Related]
10. Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma.
Singh S; Abu-Zaid A; Jin H; Fang J; Wu Q; Wang T; Feng H; Quarni W; Shao Y; Maxham L; Abdolvahabi A; Yun MK; Vaithiyalingam S; Tan H; Bowling J; Honnell V; Young B; Guo Y; Bajpai R; Pruett-Miller SM; Grosveld GC; Hatley M; Xu B; Fan Y; Wu G; Chen EY; Chen T; Lewis PW; Rankovic Z; Li Y; Murphy AJ; Easton J; Peng J; Chen X; Wang R; White SW; Davidoff AM; Yang J
Sci Transl Med; 2022 Jul; 14(653):eabq2096. PubMed ID: 35857643
[TBL] [Abstract][Full Text] [Related]
11. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract][Full Text] [Related]
12. Small molecule inhibition of PAX3-FOXO1 through AKT activation suppresses malignant phenotypes of alveolar rhabdomyosarcoma.
Jothi M; Mal M; Keller C; Mal AK
Mol Cancer Ther; 2013 Dec; 12(12):2663-74. PubMed ID: 24107448
[TBL] [Abstract][Full Text] [Related]
13. KDM3A/Ets1 epigenetic axis contributes to PAX3/FOXO1-driven and independent disease-promoting gene expression in fusion-positive Rhabdomyosarcoma.
Sobral LM; Hicks HM; Parrish JK; McCann TS; Hsieh J; Goodspeed A; Costello JC; Black JC; Jedlicka P
Mol Oncol; 2020 Oct; 14(10):2471-2486. PubMed ID: 32697014
[TBL] [Abstract][Full Text] [Related]
14. Negative correlation of single-cell
Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
[TBL] [Abstract][Full Text] [Related]
15. Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers.
Helm BR; Zhan X; Pandya PH; Murray ME; Pollok KE; Renbarger JL; Ferguson MJ; Han Z; Ni D; Zhang J; Huang K
Genes (Basel); 2019 Aug; 10(9):. PubMed ID: 31480361
[TBL] [Abstract][Full Text] [Related]
16. P/CAF mediates PAX3-FOXO1-dependent oncogenesis in alveolar rhabdomyosarcoma.
Bharathy N; Suriyamurthy S; Rao VK; Ow JR; Lim HJ; Chakraborty P; Vasudevan M; Dhamne CA; Chang KT; Min VL; Kundu TK; Taneja R
J Pathol; 2016 Nov; 240(3):269-281. PubMed ID: 27453350
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma.
Nguyen TH; Barr FG
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373318
[TBL] [Abstract][Full Text] [Related]
19. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity.
Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A
Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905
[TBL] [Abstract][Full Text] [Related]
20. The HDAC3-SMARCA4-miR-27a axis promotes expression of the
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Ishikawa Y; Zientek K; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Rudek MA; Xu L; Anders NM; Pal R; Harrold AP; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Chatterjee B; Bächinger HP; Barr FG; Liddle J; Garcia BA; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Sci Signal; 2018 Nov; 11(557):. PubMed ID: 30459282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]